Stockreport

Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Pati...

Geron Corporation  (GERN) 
Last geron corporation earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: geron.com/investors
PDF In the dose escalation Part 1 of the study, no dose-limiting toxicities were observed and the PK profiles were similar to those reported for previous monotherapy studies [Read more]